FibroBiologics, Inc. Contract Liability (Deferred Revenue)
FibroBiologics, Inc. (FBLG) had Contract Liability (Deferred Revenue) of $241.00 thousand as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2024-11-12
- 2024-09-30: Contract with Customer, Liability, Current $241.00K.
- 2024-06-30: Contract with Customer, Liability, Current $1.50M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2024-09-30 | $241.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.50M 10-Q · filed 2024-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 |